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Abstract
Background: Succinate is a Krebs cycle intermediate whose formation is enhanced 
under metabolic stress, and for which a selective sensor GPR91 has been identi-
fied on various cell types including platelets. Platelet-derived eicosanoids play pivotal 
roles in platelet activation/aggregation, which is key to thrombus formation and pro-
gression of atherothrombosis.
Objectives: This study aims to decipher the molecular mechanism(s) and potential 
involvement of eicosanoids in succinate enhanced platelet activation/aggregation.
Methods: We used liquid chromatography-mass spectrometry (LC-MS)/MS-based 
lipid mediator profiling to identify eicosanoids regulated by succinate. We ran light 
transmittance aggregometry and flow cytometry to assess platelet aggregation, 
P-selectin expression, and platelet-polymorphonuclear leukocyte (PMN) adherence. 
Various pharmacological tools were used to assess the contributions of GPR91 sig-
nalling and eicosanoids in platelet aggregation.
Results: Succinate and two types of synthetic non-metabolite GPR91 agonists—cis-epox-
ysuccinate (cES) and Cmpd131—potentiated platelet aggregation, which was partially 
blocked by a selective GPR91 antagonist XT1. GPR91 activation increased production 
of 12-hydroxy-eicosatetraenoic acid (12-HETE), thromboxane (TX) A2, and 12-hydroxy-
heptadecatrienoic acid (12-HHT) in human platelets, associated with phosphorylation 
of cytosolic phospholipase A2 (cPLA2), suggesting increased availability of free arachi-
donic acid. Blocking 12-HETE and TXA2 synthesis, or antagonism of the TXA2 recep-
tor, significantly reduced platelet aggregation enhanced by GPR91 signalling. Moreover, 
platelet-PMN suspensions challenged with succinate exhibited enhanced transcellular 
biosynthesis of leukotriene C4 (LTC4), a powerful proinflammatory vascular spasmogen.
Conclusion: Succinate signals through GPR91 to promote biosynthesis of eicosa-
noids, which contribute to platelet aggregation/activation and potentially vascular 
inflammation. Hence, GPR91 may be a suitable target for pharmacological interven-
tion in atherothrombotic conditions.
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1  | INTRODUC TION
GPR91 (Sucnr1), a sensor of extracellular succinate, is expressed in 
immune, metabolic, and cardiovascular systems.1 This receptor is 
closely related to purinergic receptors, in particular P2Y1, and has 
been strongly implicated in pathogenic processes such as hyper-
tension, ischemic tissue injury, diabetes, and immune responses.2,3 
Platelets play crucial roles in hemostasis, and their activation and 
aggregation are essential for early clot formation at sites of vascu-
lar injury.4 In addition, platelets participate in immune responses 
together with leukocytes, and are recognized as critical players in 
inflammatory processes.5,6
Eicosanoids are a series of oxygenated metabolites of ara-
chidonic acid (AA) with potent actions in hemostasis and inflam-
matory responses.7,8 Biosynthesis of eicosanoids begins with the 
release of free AA from membrane phospholipids catalyzed by 
cytosolic phospholipase A2 (cPLA2). Further metabolism of AA 
is mainly directed by two types of oxygenases, cyclooxygenases 
(COX-1 and COX-2) and lipoxygenases (5-, 12-, and 15-LOX), lead-
ing to the generation of prostaglandins, thromboxanes, hydroxy 
and dihydroxy fatty acids, including the leukotrienes, via enzymes 
in downstream pathways. Upon activation, platelets rapidly lib-
erate AA by phosphorylated and activated cPLA2 (p-cPLA2) for 
eicosanoid synthesis. The major platelet-derived eicosanoids are 
12-hydroxy-eicosatetraenoic acid (12-HETE), generated by plate-
let 12-LOX, and TXA2 together with equimolar amounts of 12-hy-
droxy-heptadecatrienoic acid (12-HHT), in a reaction catalyzed 
by TX synthase.9,10 Platelets also participate in synthesis of other 
eicosanoids, especially leukotriene C4 (LTC4), via transcellular me-
tabolism of LTA4 generated along the 5-LOX pathway by neighbor-
ing activated leukocytes.6,11
Previous work has demonstrated that succinate can potentiate 
platelet activation.12,13 Here, we sought to elucidate the molecu-
lar mechanism(s) and potential involvement of eicosanoids in this 
prothrombotic effect using liquid chromatography-mass spectrom-
etry (LC-MS)/MS based lipid mediator profiling, recently identified 
synthetic GPR91 agonists and antagonists, as well as inhibitors of 
key enzymes in the eicosanoid cascade. We report a critical role of 
GPR91 in this response as well as the ability of this metabolite recep-
tor to promote transcellular generation of pro-inflammatory LTC4.
2  | MATERIAL S AND METHODS
2.1 | Reagents
Succinate (sodium succinate dibasic hexahydrate), adenosine 5′-di-
phosphate (ADP), forskolin, and monoclonal antibody against human 
β-actin were purchased from Sigma-Aldrich. Polyclonal antibody 
against GPR91 was from Abcam, while p-ERK, ERK, p-cPLA2, cPLA2, 
COX-1 and COX-2 antibodies were from Cell Signaling Technology. 
Fluorescence-labeled antibodies against P-selectin, CD42a and 
CD45 were from Becton Dickinson. cES and Cmpd131 were cus-
tom synthesized by Enamine, Kiev, Ukraine and compound XT1 by 
Ramidus AB (Ideon Science Park). ML355, SC-560, acetylsalicylic 
acid (ASA), SQ29.548, and oxylipin standards were from Cayman 
Chemical.
2.2 | Blood collection and platelet preparation
For LC-MS/MS analysis, blood was collected from healthy volunteers 
with BD Vacutainer® ACD-A tubes, while for platelet light transmit-
tance aggregometry (LTA) BD Vacutainer® citrate tubes were used. 
All volunteers gave informed consent to donate blood (approved by 
the Ethics Committee of Karolinska Institutet Dnr 94-146) and denied 
intake of non-steroidal anti-inflammatory drugs for the past 14 days. 
The whole blood samples were centrifuged at 190 g for 10 minutes, 
and the upper two thirds of platelet rich plasma (PRP) was collected. 
Further centrifugation at 1400 g for 10 minutes yielded platelet poor 
plasma (PPP).
2.3 | Polymorphonuclear isolation and platelet/
PMN co-culture
Human polymorphonuclear (PMN)s were isolated by dextran sedi-
mentation and Ficoll-Paque Premium (GE Healthcare Bio-Sciences) 
gradient centrifugation, followed by hypotonic lysis of erythrocytes, 
yielding a purity of >99% PMNs and >96% neutrophils. PMNs were 
resuspended in phosphate buffered saline (PBS) to 2 × 107 cells/mL 
and co-incubated with PRP (1:9, v/v) in the presence of various com-
pounds at 37°C for indicated times. Incubations were stopped with 
K E Y W O R D S
antiplatelet therapy, eicosanoids, GPR91, platelet aggregation, succinate
Essentials
• GPR91 is expressed on platelets and can sense extracel-
lular succinate.
• Succinate enhances platelet aggregation, and release of 
12-HETE, TXA2, and 12-HHT via GPR91 signaling.
• Succinate-GPR91 activation enhances transcellular bio-
synthesis of LTC4 in platelet PMN suspension.
• GPR91 is a potential target for development of anti-
platelet agents.
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two volumes of methanol and soluble extracts collected for LC-MS/
MS analysis.
2.4 | Eicosanoid extraction and analysis by LC-MS/
MS
Samples were diluted 1:1 with extraction buffer (pH = 5.6) and deu-
terated internal standards were added prior to solid phase extrac-
tion (SPE). Compounds were eluted with 2.5 mL of methanol and 
evaporated under N2 gas (TurboVap LV; Biotage). Extracts were 
reconstituted to a final volume of 70 µL in methanol/water (6:1, 
v/v) and filtered using membrane spin filters (0.3 µmol/L; Merck 
Millipore Cooperation). Extracted samples and calibration standards 
were analyzed on a Acquity UPLC separation module coupled to a 
Xevo-TQXS triple quadrupole mass spectrometer (Waters Corp.) as 
previously described.14
2.5 | Light transmittance aggregometry
Light transmittance aggregometry analysis was performed on a four-
channel aggregometer (PAP-4; Bio-Data Corporation). PRP samples 
were pre-incubated with vehicle or various inhibitors/antagonists at 
37°C. ADP (1 µmol/L) was added with or without GPR91 agonists, 
and the platelet aggregation was recorded for 8 minutes. The magni-
tude of final aggregation was analyzed.
2.6 | Flow cytometry
Whole blood samples were incubated with various compounds and 
fluorescence-labeled antibodies for 20 minutes, fixed with 0.5% par-
aformaldehyde (PFA) and subjected to flow cytometric analysis of 
P-selectin surface expression and platelet-PMN aggregates as previ-
ously described.15,16
2.7 | Western blot
Pelleted platelets were lysed with radioimmunoprecipitation assay 
(RIPA) buffer and subjected to sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis (SDS-PAGE) and subsequent protein trans-
fer using an iBlot® 2 system (Thermo Fisher). Protein bands were 
visualized with enhanced chemiluminescence detection (Thermo 
Fisher).
2.8 | Statistics
All data are presented as mean ± standard error of mean (SEM). 
Differences among groups were assessed by one-way, two-way 
analysis of variance (ANOVA) or Student's t-test and a value of 
P < .05 was considered statistically significant.
3  | RESULTS AND DISCUSSION
3.1 | GPR91 signaling enhances ADP-mediated 
platelet activation and aggregation
Robust expression of GPR91 in platelets was detected by western 
blot analysis (Figure 1A). We then challenged PRP with ADP together 
with succinate or any of two synthetic non-metabolite agonists of 
GPR91, namely cES or Cmpd131. While cES is a conformationally 
constrained succinate analog, Cmpd131 is a larger backbone modi-
fied analog with an amide-linked hydrophobic “side chain,” which fits 
into a side pocket of GPR91.17,18 Succinate, the endogenous recep-
tor ligand, and the two synthetic agonists all enhanced ADP-induced 
platelet aggregation (Figure 1). We also synthesized a potent and 
selective antagonist of GPR91, here denoted XT1, according to a 
previously published synthetic strategy (Compound 4c in19). Pre-
incubation with XT1 partially inhibited the effect of succinate lend-
ing further support to the notion that GPR91 plays an essential role 
in this response (Figure 1E).
3.2 | GPR91 agonists elicit 12-HETE, TXA2, and 12-
HHT production from human platelets
In search of lipid mediators that could be involved in succinate-
enhanced platelet aggregation, we directly assessed the forma-
tion of oxygenated derivatives of polyunsaturated fatty acids 
(AA, EPA, DHA, and LA) in PRP upon GPR91 activation by 
LC-MS/MS quantification. Within the panel of analytes, 46 lipid 
species were detected, with only six AA derivatives (for which 
the biosynthetic routes are depicted in Figure 2A) influenced 
by succinate challenge (Figure 2B). By far the most abundant 
eicosanoids produced by platelets challenged with 1 mmol/L 
succinate were 12-HETE, TXA2, and 12-HHT (Figure 2C). Minor 
amounts of PGD2, PGE2, and PGF2α were also detected, probably 
reflecting COX-1 activity. Similar effects were observed for cES 
(Figure 2C,D), with a more efficient induction of 12-HETE from 
platelets by cES than succinate. Succinate and cES increased 
the phosphorylation of cPLA2 and ERK but not p38 MAPK 
(Figure 2E), which translates to increased liberation of AA from 
phospholipids and more substrate for eicosanoid generation.20 
As expected, COX-1 protein level was not influenced by succi-
nate or cES treatments (Figure 2E), and there was no detectable 
COX-2 protein in any of the treatment groups. Furthermore, suc-
cinate potentiated TXA2 production in ADP-challenged platelets, 
and pre-incubation with 1 µmol/L XT1, significantly inhibited this 
effect (Figure 2F). Together, these results indicate that GPR91 
ligation primarily leads to activation of ERK and cPLA2, which in 
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turn promotes eicosanoid biosynthesis from human platelets via 
COX and LOX pathways.
3.3 | Targeting 12-LOX, COX, and TP receptor 
ameliorate GPR91-potentiated platelet activation
As 12-HETE was one of the major eicosanoids triggered by GPR91 
ligation (Figure 2B), a 12-LOX inhibitor-ML355 was used to assess 
the role of 12-LOX products (12-HpETE and 12-HETE) in succi-
nate-potentiated aggregation induced by ADP. Pre-incubation with 
ML355 significantly inhibited this succinate potentiation (Figure 3A), 
suggesting an involvement of 12-LOX. Inhibition of platelet COX-1 
by ASA or the selective inhibitor SC-560 also reduced succinate-
enhanced platelet aggregation (Figure 3B,C) as did the TP receptor 
antagonist SQ29.548 (Figure 3D). Moreover, the combination of 
ML355 with ASA, SC-560, or SQ29.548 showed a more effective 
inhibitory effect on platelet aggregation than did any of the agents 
alone. These results suggest that 12-LOX product(s) and TXA2 are 
involved in GPR91 potentiated platelet aggregation induced by 
ADP (Figure 3). Succinate also promoted formation of 12-HHT, a 
side product of TXA2 biosynthesis (Figure 2). This compound is the 
high-affinity ligand of the BLT2 receptor21 and may elicit responses 
in neighboring leukocytes. However, it should be noted that the 
role of BLT2 in cells of the vascular system is poorly understood.
3.4 | Succinate-GPR91 activation enhances platelet-
dependent conversion of neutrophil-derived LTA4 
to LTC4
Platelets not only produce eicosanoids by themselves, but can also 
cooperate with neighboring cells to produce lipid mediators through 
transcellular metabolism.22 Because it has been reported that succi-
nate can increase platelet surface expression of P-selectin, we asked 
whether this effect would be sufficient to promote transcellular 
F I G U R E  1   GPR91 activation potentiates platelet aggregation. A, Western blot analysis of GPR91 and Beta-actin expression in human 
monocyte-derived macrophage (Mac), platelet (Plt), and polymorphonuclear (PMN), with band intensity of GPR91 normalized by Beta-
actin as indication of GPR91 expression (n = 3). B-D, Vehicle, 1 mmol/L succinate, 1 mmol/L cES, or 100 µmol/L Cmpd131 was added with 
or without 1 µmol/L adenosine 5′-diphosphate (ADP) and aggregation assessed with the light transmittance aggregometry (LTA) assay 
(n = 4). E, Platelets were pre-incubated with vehicle or 1 µmol/L XT1 for 1 hour, followed by succinate or cES added with ADP to assess the 
aggregation magnitude of platelets (n = 3). *P < .05, **P < .01
GPR91
A B C
D E
38 kDa
Beta-actin
1.5
Mac PIt PMN
1.0
0.5
0.0
100
80
60
40
ns
20
0
100 **
*
80
60
40
20
0
ADP ADP
+Succ
ADP
+cES
100
80
60
40
20
0
100 Vehicle
XT1
ns
*
80
60
40
20
0
*
ADP ADP
+Cmpd131
Ag
gr
eg
at
io
n 
(%
)
Ag
gr
eg
at
io
n 
(%
)
Ag
gr
eg
at
io
n 
(%
)
G
PR
91
 e
xp
re
ss
io
n 
(A
.U
.)
*
Ve
hic
le
Su
cc
AD
P+
Su
cc
AD
P
Ag
gr
eg
at
io
n 
(%
)
*
ADP ADP+Succ ADP+cES
980  |     TANG eT Al.
F I G U R E  2   Activation of GPR91 
triggers 12-hydroxy-eicosatetraenoic acid 
(12-HETE), thromboxane A2 (TXA2), and 
12-hydroxy-heptadecatrienoic acid (12-
HHT) production from human platelets. A, 
Biosynthetic routes of eicosanoids from 
membrane phospholipids. B-D, Platelets 
were incubated with vehicle, 1 mmol/L 
succinate, 1 mmol/L cES, or 100 µmol/L 
Cmpd131 at 37°C for 30 minutes. The 
reaction was stopped by two volumes 
of methanol followed by lipid mediator 
extraction and quantification by liquid 
chromatography-mass spectrometry 
(LC-MS)/MS (n = 6). B, Red and orange 
dots: arachidonic acid (AA) derivatives 
influenced by succinate challenge. Blue 
dots: Other oxygenated derivatives of 
polyunsaturated fatty acids. C, Absolute 
levels of AA derivatives influenced by 
succinate or cES (n = 6). D, Comparison 
of 12-HETE, TXB2, 12-HHT production 
from platelets challenged with succinate 
or cES (n = 6). E, Western blot analysis of 
total protein from platelets treated with 
succinate and cES at 37°C for 30 minutes 
(n = 3). F, Platelets were pre-incubated 
with vehicle or 1 µmol/L XT1 for 1 hour, 
followed by adenosine 5′-diphosphate 
(ADP) added with or without succinate 
for 30 minutes. TXB2 level in supernatant 
was assessed by ELISA (n = 4). *P < .05, 
**P < .01, ***P < .001
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biosynthetic processes. We chose mixed platelet-PMN suspensions 
for assessment of transcellular biosynthesis of leukocyte-derived 
LTA4 into LTC4,
11 because there is a distinct partitioning of critical 
enzymes between platelets (recipient, containing LTC4 synthase/
LTC4S) and PMNs (donor, harboring 5-LOX for production of LTA4).
In our hands, succinate as well as cES enhanced P-selectin surface 
expression in human platelets (Figure 4A,B), suggesting an involve-
ment of GPR91 in platelet-neutrophil interactions. Furthermore, 
platelet PMN suspensions challenged with succinate indeed pro-
moted LTC4 production as determined by LC-MS/MS analysis 
(Figure 4C). In contrast, there was no change of LTB4 or 5-HETE pro-
duction in succinate treated suspensions (Figure 4D,E), suggesting 
neutrophils are not activated by succinate treatment. Also, whole 
blood supplied with succinate showed a higher level of platelet-PMN 
adherence (Figure 4G), in line with our observation of P-selectin sur-
face expression and LTC4 production in succinate-treated platelets 
and platelet PMN suspension.
Of note, when synthetic exogenous LTA4 (10 µmol/L) was used 
as the substrate source, PRP incubated with succinate produced 
more LTC4 than control (Figure 4F), suggesting succinate increases 
LTC4S activity in platelets. LTC4S is post-translationally regulated by 
phosphorylation that reduces enzyme activity.23 Therefore, one may 
speculate that succinate can activate a protein phosphatase acting 
on LTC4S resulting in enhanced enzyme activity. Further studies will 
be required to understand the mechanism underlying the effect of 
succinate on LTC4S activation.
3.5 | Therapeutic implications of succinate-GPR91-
eicosanoid signaling
Our data add GPR91 to at least three previously identified lev-
els at which pharmacological intervention could reduce platelet 
activation and aggregation (COX-1, the platelet TXA2 receptor, 
and 12-LOX). Low-dose ASA targets COX and is widely used for 
this purpose, while thromboxane receptor antagonists have been 
developed without making it to clinical settings. 12-LOX and 12-
HETE have been implicated in platelet functions and thrombus 
formation24 and recently, ML355, a potent and selective 12-LOX 
inhibitor, was suggested to impair platelet reactivity and clotting.25 
In fact, as ASA could only partially inhibit succinate potentiated 
platelet aggregation12 (Figure 3B), the effectiveness of ML355 in 
F I G U R E  3   TXA2 and 12-LOX product(s) are involved in succinate-potentiated platelet aggregation. A-D, Platelets were incubated at 37°C 
for 5 minutes with vehicle or (A) 50 µmol/L ML355 (n = 4), (B) 50 µmol/L ASA with or without 50 µmol/L ML355 (n = 6), (C) 5 µmol/L SC-560 
with or without 50 µmol/L ML355 (n = 4), and (D) 5 µmol/L SQ29.548 with or without 50 µmol/L ML355 (n = 4). Afterwards, aggregation 
was assessed following induction by 1 µmol/L adenosine 5′-diphosphate (ADP) and 1 mmol/L succinate. *P < .05, **P < .01, ***P < .001
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F I G U R E  4   Succinate promotes transcellular biosynthesis of leukotriene C4 (LTC4). A-B, Whole blood was incubated with various 
compounds in HEPES buffer with fluorescence labeled P-selectin antibody at room temperature for 20 minutes, the cells were then 
fixed with 0.5% paraformaldehyde (PFA) and analyzed by fluorescence-activated cell sorting (FACS). C-E, Platelets and platelet-
polymorphonuclear leukocytes (PMNs) were cocultured with 1 mmol/L succinate at 37°C for 30 minutes. The reaction was stopped by two 
volumes of methanol and lipid mediators were analyzed by liquid chromatography-mass spectrometry (LC-MS)/MS. F, 10 µmol/L LTA4 with 
or without 1 mmol/L succinate was added to platelets and incubated at 37°C for 30 minutes. The reaction was stopped by two volumes of 
methanol and the lipid mediators were analyzed by LC-MS/MS. G, Whole blood was incubated with various compounds in HEPES buffer 
with fluorescence labeled CD45 and CD42a antibodies at room temperature for 20 minutes, the cells were then fixed with 0.5% PFA and 
analyzed by FACS. *P < .05
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the current study supports targeting 12-LOX as a potential new 
antiplatelet therapy, especially in patients with ASA resistance or 
intolerance.
Succinate activates platelets with increased surface exposure 
of P-selectin, which promotes formation of platelet-neutrophil ag-
gregates6,26 and transcellular biosynthesis of LTC4.
27 This cooper-
ative action could be an important source of LTC4 under certain 
circumstances as both cell types are fast-reacting components in 
inflammation, especially in aspirin-exacerbated respiratory dis-
ease.28 In fact, this notion can be extended to atherosclerosis and 
associated cardiovascular diseases. For instance, the recruitment 
of neutrophils into atherosclerotic lesion is partially dependent on 
activated platelets, which further promotes early lesional devel-
opment of atherosclerosis.29 Another example is the vulnerable 
atherosclerotic plaque, which is prone to rupture and thrombus 
formation. Although the pathogenic mechanism(s) are not well 
understood it is believed to involve exposure of plaque lipids and 
immune cells, which in turn activates platelets leading to clot-
ting, a scenario potentially involving transcellular biosynthesis of 
leukotrienes.
The autocrine and paracrine regulatory mechanism through 
which succinate acts as a ligand for GPR91 now introduces a novel 
possibility for interfering with platelet activation. Succinate is gen-
erated and excreted by many different cell types under metabolic 
stress including hypoxia.30 Here we find that succinate promotes 
platelet activation and aggregation as well as transcellular biosynthe-
sis of the pro-inflammatory LTC4. Thus, LTC4, the parent compound 
of the spasmogenic and immune regulatory cysteinyl-leukotrienes, 
could be formed when clotting platelets attach to inflammatory cells 
of, for example, the vulnerable plaque. It appears that GPR91 antag-
onists could be a novel means to block this process.
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